News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Kyowa Hakko Kirin News Releases 2013

December 23, 2013
Launch of Redesigned BioWa Website
December 20, 2013
Approval for Additional Indication for Unresectable Pancreatic Cancer of 5-FU Injection 250mg and 1000mg
December 20, 2013
Co-Promotion Partnership Agreement for Topical Calcipotriol/Betamethasone Dipropionate in Japan
December 16, 2013
Launch of Kyowa Hakko Kirin Thailand Website
December 11, 2013
New window opensLonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with MedImmunePDF file:New window opens(92KB)
December 11, 2013
Launch of Abstral® sublingual tablets for Cancer Pain Treatment in Japan
December 2, 2013
Yokkaichi Plant Closed as Part of Production Facility Reorganization
December 2, 2013
Launch of Kyowa Hakko Kirin Singapore Website
November 28, 2013
Launch of Redesigned Kyowa Hakko Kirin Korea Website
November 22, 2013
Approval for Pediatric Use of Topina®Tablets, an Antiepileptic Agent
November 21, 2013
Kyowa Hakko Kirin Initiates a Global Phase 3 Trial of Istradefylline (KW-6002) for Parkinson's Disease
November 20, 2013
Launch of Sancuso in Taiwan
November 11, 2013
New window opensProStrakan Announces Board ChangesPDF file:New window opens(127KB)
November 11, 2013
Kyowa Hakko Kirin Announces the Development Status of Bardoxolone Methyl (RTA 402) in Patients with Chronic Kidney Disease and Type 2 Diabetes in Japan
October 31, 2013
Results of a Phase 2 Study of KHK4827 in Subjects with Psoriasis in Japan
October 31, 2013
Launch of Nplate in Taiwan
October 29, 2013
Notice of revisions to the Appendix to the Fiscal 2013 Third Quarter Consolidated Financial Statements issued on October 25, 2013PDF file:New window opens(323KB)
October 25, 2013
Kyowa Hakko Kirin Third Quarter Operating Income up 10.9%PDF file:New window opens(122KB)
October 25, 2013
Consolidated Financial Summary Fiscal 2013, Third QuarterPDF file:New window opens(302KB)
October 25, 2013
Appendix to the Fiscal 2013 Third Quarter Consolidated Financial StatementsPDF file:New window opens(301KB)
October 21, 2013
Kyowa Hakko Kirin launched a website content "Invisible Things" for its corporate branding.
View the artistically created films which express the condensed feelings of our company members, called "Commitment to Life"
October 7, 2013
Announcement of Results from a Single Dose Phase 1 Study of a Human Monoclonal Anti-FGF23 Antibody (KRN23) in X-linked Hypophosphatemia in Adults
October 1, 2013
Launch of Redesigned Kyowa Hakko Kirin China Website
September 30, 2013
New window opensProStrakan Announces EU Launch of SancusoPDF file:New window opens(76KB)
September 26, 2013
Subanalyses of the SAVOR clinical trial for Onglyza® will be presented at the 49th Annual Meeting of the European Association for the Study of DiabetesPDF file:New window opens(95KB)
September 20, 2013
Announcement regarding the Marketing Approval of Abstral® sublingual tablets for Cancer Pain Treatment
September 20, 2013
Approval of Long-Acting Erythropoiesis-Stimulating Agent NESP® Injection 5μg Plastic Syringe in Japan
September 13, 2013
Approval of Additional Indication of Long-Acting Erythropoiesis-Stimulating Agent NESP® for Pediatric Patients with renal anemia in Japan
September 13, 2013
Launch of Kyowa Hakko Kirin Hong Kong Corporate Website
September 9, 2013
Kyowa Hakko Kirin Establishes "Singapore Translational Research Laboratory (STRL)"
- Initiates Research Collaboration with the Cancer Science Institute of Singapore and the National University Cancer Institute, Singapore
PDF file:New window opens(77KB)
September 4, 2013
Collaboration with Ultragenyx to Develop and Commercialize KRN23 for X-linked Hypophosphatemia
September 2, 2013
Results of the SAVOR-TIMI53 clinical trial for Onglyza® will be presented at the European Society of Cardiology Congress and published in the New England Journal of MedicinePDF file:New window opens(59KB)
August 27, 2013
Launch of Redesigned Kyowa Hakko Kirin California Website
July 31, 2013
Hisamitsu Pharmaceutical Submits Application Seeking Approval for Additional Indication of Chronic Pain for Fentos® Tape, a Transdermal Long-Acting Cancer Pain Relief Patch
July 31, 2013
Notice of revisions to the figures in Result Presentation for first half of the fiscal year ending December 2013PDF file:New window opens(1399KB)
July 30, 2013
New window opensLonza and BioWa Sign License Agreements with Pfizer, Inc. Allowing Use of Their POTELLIGENT® CHOK1SV Cell Line for Therapeutic Antibody Research and DevelopmentPDF file:New window opens(53KB)
July 30, 2013
New window opensLa Jolla Institute Continues Longtime Collaboration With Kyowa Hakko Kirin California
Signing Extends One of World’s Most Enduring Alliances for Drug Discovery
PDF file:New window opens(275KB)
July 26, 2013
Kyowa Hakko Kirin First Half Operating Income up 6.2%PDF file:New window opens(117KB)
July 26, 2013
Consolidated Financial Summary Fiscal 2013 InterimPDF file:New window opens(255KB)
July 26, 2013
Appendix to the Fiscal 2013 Interim Consolidated Financial StatementsPDF file:New window opens(357KB)
July 26, 2013
FY ending December 2013 First half results presentationPDF file:New window opens(1197KB)
July 19, 2013
Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab
July 16, 2013
Daiichi Fine Chemical Completes Construction of a New Facility for the Manufacture of Bulk PharmaceuticalsPDF file:New window opens(98KB)
July 9, 2013
New window opensProStrakan Announces 3 Abstracts for Sancuso®(Granisetron Transdermal System) Presented at the Multinational Association for Supportive Care in Cancer (MASCC) 2013 Annual MeetingPDF file:New window opens(155KB)
July 8, 2013
Launch of Onglyza® Tablets 2.5mg, 5mg for Type 2 Diabetes
June 28, 2013
Launch of Kyowa Hakko Kirin Taiwan Corporate Website
June 27, 2013
Kyowa Hakko Kirin Submits Application for Approval in Japan for Sustained-Duration G-CSF Product (KRN125)
June 27, 2013
Application Seeking Approval for Additional Indication for REGPARA® Tablets 25mg and 75mg
June 17, 2013
Launch of Renewed Kyowa Hakko Kirin Corporate Website
May 31, 2013
Application Seeking Approval for Additional Indication for Pancreatic Cancer of 5-FU Injection 250mg and 1000mg
May 29, 2013
Launch of NOURIAST® tablets 20 mg, in Japan, a novel antiparkinsonian agent
May 27, 2013
Kyowa Hakko Kirin Subsidiary Chiyoda Kaihatsu
To Transfer Some Operations to Uyeno Kosan
May 24, 2013
Completion of Drug Price Listing and Marketing Authorization Transfer of Onglyza® Tablets 2.5mg, 5mg for Type 2 Diabetes
April 26, 2013
Notice of revisions to the Appendix to the Fiscal 2013 First Quarter Consolidated Financial Statements issued on April 24, 2013PDF file:New window opens(416KB)
April 24, 2013
Kyowa Hakko Kirin Announces Q1 resultsPDF file:New window opens(111KB)
April 24, 2013
Consolidated Financial Summary First Quarter of the Fiscal Year to December 31, 2013PDF file:New window opens(113KB)
April 24, 2013
Appendix to the Fiscal 2013 First Quarter Consolidated Financial StatementsPDF file:New window opens(229KB)
April 4, 2013
An article, "Japan's biggest biotech" is on BioCenturyPDF file:New window opens(57KB)
March 29, 2013
Matters concerning controlling shareholdersPDF file:New window opens(53KB)
March 25, 2013
Approval for manufacturing and marketing of NOURIAST® tablets 20 mg, a novel antiparkinsonian agent
March 25, 2013
Otsuka Obtains Marketing Approval in Japan
for Onglyza® Tablets to Treat Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin
March 25, 2013
Approval for Additional Indication of Pheochromocytoma for Dacarbazine Injection 100PDF file:New window opens(14KB)
March 25, 2013
Launch of "MINIRINMELT® OD Tablet 60μg"
A Treatment of Central Diabetes Insipidus
March 22, 2013
Notice regarding allotment of stock acquisition rights(stock compensation-type stock options)PDF file:New window opens(39KB)
March 18, 2013
New window opensBioWa Announces Office Relocation to La Jolla, CaliforniaPDF file:New window opens(56KB)
March 8, 2013
Announcement of Results from a Japanese Phase 3 Clinical Trial on the Additional Indication of Chronic Pain for Fentos® Tape (Development Code: HFT-290), a Transdermal Long-Acting Cancer Pain Relief Patch
March 7, 2013
Construction Work Commenced for Drug Product Manufacturing Facility at Takasaki Plant
February 28, 2013
Approval for time-window extension of the thrombolytic agents GRTPA® and ACTIVACIN® up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular diseasePDF file:New window opens(164KB)
February 21, 2013
Pasetocin® and Sawacillin®: Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole
February 21, 2013
Approval for Additional Indications for Intramuscular Administration and Dosage of Leunase® Injection
February 21, 2013
Position and policies concerning the reduction of the minimum investment unitPDF file:New window opens(40KB)
February 21, 2013
Notice regarding stock acquisition rights for the purpose of granting stock compensation-type stock optionsPDF file:New window opens(80KB)
January 31, 2013
Kyowa Hakko Kirin Group: Medium-term Business Plan 2013-2015PDF file:New window opens(56KB)
January 31, 2013
Medium-term business plan FY 2013 to 2015PDF file:New window opens(3891KB)
January 31, 2013
Kyowa Hakko Kirin Fiscal 2012 Results : Record operating income for third consecutive yearPDF file:New window opens(95KB)
January 31, 2013
Consolidated Financial Summary Fiscal 2012 (January 1, 2012-December 31, 2012)PDF file:New window opens(476KB)
January 31, 2013
Appendix to the Fiscal 2012 Consolidated Financial StatementsPDF file:New window opens(268KB)
January 31, 2013
Kyowa Hakko Kirin Fiscal 2012 Results MeetingPDF file:New window opens(432KB)
January 25, 2013
Results of Phase 3 Clinical Trials of KRN125 in Patients with Malignant Lymphoma and Breast Cancer in Japan
January 4, 2013
Completion of a transfer of business involving consolidated subsidiary Hematech, Inc.PDF file:New window opens(8KB)

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.



To Page Top